A Phase 1, Open-label Trial to Evaluate Target Occupancy of CVL-231 at Muscarinic Receptors Type 4 in Brain Following Single Oral Doses Using Positron Emission Tomography in Healthy Adult Subjects
Who is this study for? Adult patients with Schizophrenia
What treatments are being studied? CVL-231 Muscarinic Acetylcholine Receptor Activator
Status: Completed
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
PET Trial to Evaluate Target Occupancy of CVL-231 at Muscarinic Receptors Type 4 in Brain Following Oral Dosing
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 55
Healthy Volunteers: t
View:
• Healthy male subjects and female subjects of nonchildbearing potential, ages 18 to 55 years, inclusive, at the time of signing the ICF
• Sexually active men with a pregnant or a nonpregnant partner of childbearing potential must agree to use a double-barrier method of birth control, including a condom, and practice contraception during treatment and through 7 days post dose
• Capable of providing informed consent and following study requirements
Locations
United States
Massachusetts
Massachusetts General Hospital Translational and Clinical Research Centers
Boston
Other Locations
Belgium
UZ Leuven
Leuven
Time Frame
Start Date: 2021-06-01
Completion Date: 2023-07-14
Participants
Target number of participants: 15
Treatments
Experimental: CVL-231
Related Therapeutic Areas
Sponsors
Leads: Cerevel Therapeutics, LLC